Keji Pharmaceutical-B (02171) fell more than 8% in the afternoon. As of press release, it was down 7.66% to HK$5.91, with a turnover of HK$7.542,900.
The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) fell by more than 8% in the afternoon. As of press release, it was down 7.66% to HK$5.91, with a turnover of HK$7.542,900.
According to the news, recently, Keji Pharmaceutical announced that the company's CAR-T cell therapy product Sekaiser (Zevorkiolen injection) has been officially approved and marketed by the State Drug Administration. The drug is used to treat adult patients with recurrent or refractory multiple myeloma.
Keji Pharmaceutical said that the initial price of the company's CAR-T therapy Saekaize was 1.15 million yuan. The company will actively help patients receive support such as Huimin Insurance and commercial insurance. It is hoped that in the future, there will be more diversified payment methods to improve the accessibility of CAR-T treatment. At the same time, it will monitor national health insurance policy developments with Huadong Pharmaceutical, and participate in and seek relevant policy support while comprehensively considering factors such as cost and patient accessibility. In terms of revenue, Saikaiser's annual terminal sales are expected to peak at more than 1 billion yuan.